Phoenix Investment Adviser’s Aerie Pharmaceuticals AERI Stock Holding History

Phoenix Investment Adviser’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,300	Closed	-$38K	–	40
2019 Q2	$38K	Sell	1,300 -250	-16%	-$9.63K	0.07%	36
2019 Q1	$74K	Buy	1,550 +100	+7%	+$4.4K	0.16%	31
2018 Q4	$52K	Buy	1,450 +250	+21%	+$11.7K	0.11%	26
2018 Q3	$74K	Hold	1,200	–	–	0.1%	36
2018 Q2	$81K	Buy	1,200 +200	+20%	+$11.2K	0.15%	31
2018 Q1	$54K	Buy	1,000 +700	+233%	+$39.1K	0.1%	31
2017 Q4	$18K	Hold	300	–	–	0.02%	53
2017 Q3	$15K	Hold	300	–	–	0.01%	54
2017 Q2	$16K	Hold	300	–	–	0.01%	50
2017 Q1	$14K	Buy	+300	New	+$13.4K	0.01%	59
2016 Q4	–	Sell	-12,500	Closed	-$472K	–	64
2016 Q3	$472K	Buy	+12,500	New	+$276K	0.39%	38

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Phoenix Investment Adviser's AERI Position: Q3 2019 in Review

Phoenix Investment Adviser sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 1,300 shares — an estimated $38K sold.

Phoenix Investment Adviser first reported a position in AERI in Q3 2016 and held it in 11 quarters. The position peaked at $472K in Q3 2016. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

Phoenix Investment Adviser reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Phoenix Investment Adviser sold 1,300 Aerie Pharmaceuticals shares in Q3 2019, an estimated $38K.
Phoenix Investment Adviser first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 11 quarters.
Phoenix Investment Adviser's Aerie Pharmaceuticals position peaked at $472K in Q3 2016.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Phoenix Investment Adviser's 13F filing for Q3 2019, filed 13 Nov 2019.